Blood level check for kidney cancer drug: did it predict side effects?
NCT ID NCT03846128
First seen Apr 26, 2026 · Last updated May 25, 2026 · Updated 5 times
Summary
This study aimed to find out if the amount of sunitinib (a targeted therapy) in the blood of people with metastatic kidney cancer is linked to severe side effects or how well the treatment works. Researchers planned to collect extra blood samples during routine tests from 6 patients starting sunitinib as their first treatment. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC KIDNEY CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de ROUEN
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.